Thomas J. Saphner
Advanced in Breast Cancer

Dr. Thomas J. Saphner

Hematology | Oncology
Aurora Healthcare
Vince Lombardi Cancer Clinic
5300 Memorial Dr, 
Two Rivers, WI 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Breast Cancer
Aurora Healthcare
Vince Lombardi Cancer Clinic
5300 Memorial Dr, 
Two Rivers, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Thomas Saphner is a Hematologist and an Oncologist in Two Rivers, Wisconsin. Dr. Saphner is rated as an Advanced provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Paget Disease of the Breast, Upper Tract Urothelial Carcinoma (UTUC), Inflammatory Breast Cancer, and Angiosarcoma.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 16 articles and participated in 3 clinical trials in the study of Breast Cancer.

Residency
University of Kentucky
Specialties
Hematology
Oncology
Licenses
Internal Medicine in MI
Board Certifications
American Board Of Internal Medicine
Fellowships
University of Wisconsin Hospital and Clinics, Medical Oncology
Hospital Affiliations
Bay Area Medical Center
Aurora Health Care Central Inc
Aurora Baycare Medical Ctr
Aurora Medical Ctr Manitowoc County
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare
  • OTHER COMMERCIAL
Common Ground Healthcare Cooperative
  • EPO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Network Health
  • HMO
Quartz
  • HMO
  • POS
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Vince Lombardi Cancer Clinic
5300 Memorial Dr, Two Rivers, WI 54241
Call: 920-793-6100
Other Locations
Aurora Cancer Care
3003 University Dr, Marinette, WI 54143
Vince Lombardi Cancer Clinic
855 N Westhaven Dr, Oshkosh, WI 54904

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent
Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Other
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)
Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)
Enrollment Status: Active_not_recruiting
Publish Date: October 30, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study
NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Procedure
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Behavioral
Study Phase: Phase 3
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Other
EROS: Engendering Reproductive Health Within Oncologic Survivorship
EROS: Engendering Reproductive Health Within Oncologic Survivorship
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other
Study Phase: Not Applicable
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Implementing a Virtual Tobacco Treatment in Community Oncology Practices: Smoke Free Support Study 2.0
Implementing a Virtual Tobacco Treatment in Community Oncology Practices: Smoke Free Support Study 2.0
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Other, Drug
Study Phase: Not Applicable
Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients With Cancer
Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients With Cancer
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Other, Drug
Study Drug: Ibuprofen
Study Phase: Phase 2
A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors With Cognitive Impairment
A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors With Cognitive Impairment
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drug: Donepezil 
Study Phase: Phase 3
View 14 Less Clinical Trials

18 Total Publications

A qualitative examination of cognitive behavioral therapy strategies and health management content to reduce fear of cancer recurrence among breast cancer survivors: Results from the FoRtitude study.
A qualitative examination of cognitive behavioral therapy strategies and health management content to reduce fear of cancer recurrence among breast cancer survivors: Results from the FoRtitude study.
Journal: Journal of health psychology
Published: July 28, 2025
View All 18 Publications
Similar Doctors
Amritha C. Karkera
Advanced in Breast Cancer
Dr. Amritha C. Karkera
Hematology | Oncology
Advanced in Breast Cancer
Dr. Amritha C. Karkera
Hematology | Oncology

Vince Lombardi Cancer Clinic

2845 Greenbrier Rd, Ste 250, 
Green Bay, WI 
 (43.5 miles away)
920-288-4180
Languages Spoken:
English, Hindi, Kannada
See accepted insurances

Amritha Karkera is a Hematologist and an Oncologist in Green Bay, Wisconsin. Dr. Karkera is rated as an Advanced provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Ovarian Carcinosarcoma, and Virilizing Ovarian Tumor.

Distinguished in Breast Cancer
Dr. Shannon L. Schmidt
Hematology Oncology | Hematology | Oncology
Distinguished in Breast Cancer
Dr. Shannon L. Schmidt
Hematology Oncology | Hematology | Oncology

Thedacare Incorporated

333 N Green Bay Rd, 
Neenah, WI 
 (73.1 miles away)
920-720-2300
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shannon Schmidt is a Hematologist Oncology specialist and a Hematologist in Neenah, Wisconsin. Dr. Schmidt has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, B-Cell Lymphoma, Angiosarcoma, and Bone Marrow Aspiration. Dr. Schmidt is currently accepting new patients.

Distinguished in Breast Cancer
Dr. Ranveer K. Nand
Hematology Oncology | Hematology | Oncology
Distinguished in Breast Cancer
Dr. Ranveer K. Nand
Hematology Oncology | Hematology | Oncology

Columbia St Marys Hospital Milwaukee Inc

13111 N Port Washington Rd, 
Mequon, WI 
 (126.1 miles away)
262-243-7300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ranveer Nand is a Hematologist Oncology specialist and a Hematologist in Mequon, Wisconsin. Dr. Nand is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Paget Disease of the Breast, Inflammatory Breast Cancer, Breast Cancer, and Angiosarcoma. Dr. Nand is currently accepting new patients.

VIEW MORE BREAST CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Saphner's expertise for a condition
ConditionClose
    • Distinguished
    • Paget Disease of the Breast
      Dr. Saphner is
      Distinguished
      . Learn about Paget Disease of the Breast.
      See more Paget Disease of the Breast experts
    • Advanced
    • Angiosarcoma
      Dr. Saphner is
      Advanced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Breast Cancer
      Dr. Saphner is
      Advanced
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Familial Prostate Cancer
      Dr. Saphner is
      Advanced
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    • Inflammatory Breast Cancer
      Dr. Saphner is
      Advanced
      . Learn about Inflammatory Breast Cancer.
      See more Inflammatory Breast Cancer experts
    • Lung Cancer
      Dr. Saphner is
      Advanced
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    • Muscle Invasive Bladder Cancer
      Dr. Saphner is
      Advanced
      . Learn about Muscle Invasive Bladder Cancer.
      See more Muscle Invasive Bladder Cancer experts
    View All 10 Advanced Conditions
    • Experienced
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Saphner is
      Experienced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • Adenoid Cystic Carcinoma
      Dr. Saphner is
      Experienced
      . Learn about Adenoid Cystic Carcinoma.
      See more Adenoid Cystic Carcinoma experts
    • Adult Immune Thrombocytopenia
      Dr. Saphner is
      Experienced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Adult Soft Tissue Sarcoma
      Dr. Saphner is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Saphner is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Saphner is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    View All 78 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

        Close
        0 / 1000

        Please provide us with the below insurance information:

              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.